| |  Online-Ressource |
|---|
| Verfasst von: | Budczies, Jan [VerfasserIn]  |
|---|
| | Kirchner, Martina [VerfasserIn] |
|---|
| | Kluck, Klaus [VerfasserIn] |
|---|
| | Kazdal, Daniel [VerfasserIn] |
|---|
| | Glade, Julia [VerfasserIn] |
|---|
| | Allgäuer, Michael [VerfasserIn] |
|---|
| | Kriegsmann, Mark [VerfasserIn] |
|---|
| | Heußel, Claus Peter [VerfasserIn] |
|---|
| | Herth, Felix [VerfasserIn] |
|---|
| | Winter, Hauke [VerfasserIn] |
|---|
| | Meister, Michael [VerfasserIn] |
|---|
| | Muley, Thomas [VerfasserIn] |
|---|
| | Goldmann, Torsten [VerfasserIn] |
|---|
| | Fröhling, Stefan [VerfasserIn] |
|---|
| | Wermke, Martin [VerfasserIn] |
|---|
| | Waller, Cornelius [VerfasserIn] |
|---|
| | Tufman, Amanda L. H. [VerfasserIn] |
|---|
| | Reck, Martin [VerfasserIn] |
|---|
| | Peters, Solange [VerfasserIn] |
|---|
| | Schirmacher, Peter [VerfasserIn] |
|---|
| | Thomas, Michael [VerfasserIn] |
|---|
| | Christopoulos, Petros [VerfasserIn] |
|---|
| | Stenzinger, Albrecht [VerfasserIn] |
|---|
| Titel: | Deciphering the immunosuppressive tumor microenvironment in ALK- and EGFR-positive lung adenocarcinoma |
|---|
| Verf.angabe: | Jan Budczies, Martina Kirchner, Klaus Kluck, Daniel Kazdal, Julia Glade, Michael Allgäuer, Mark Kriegsmann, Claus-Peter Heußel, Felix J. Herth, Hauke Winter, Michael Meister, Thomas Muley, Torsten Goldmann, Stefan Fröhling, Martin Wermke, Cornelius F. Waller, Amanda Tufman, Martin Reck, Solange Peters, Peter Schirmacher, Michael Thomas, Petros Christopoulos, Albrecht Stenzinger |
|---|
| E-Jahr: | 2022 |
|---|
| Jahr: | 14 June 2021 |
|---|
| Jahr des Originals: | 2021 |
|---|
| Umfang: | 15 S. |
|---|
| Fussnoten: | Gesehen am 05.05.2023 |
|---|
| Titel Quelle: | Enthalten in: Cancer immunology immunotherapy |
|---|
| Ort Quelle: | Berlin : Springer, 1976 |
|---|
| Jahr Quelle: | 2022 |
|---|
| Band/Heft Quelle: | 71(2022), 2, Seite 251-265 |
|---|
| ISSN Quelle: | 1432-0851 |
|---|
| Abstract: | The advent of immune checkpoint blockade (ICB) has led to significantly improved disease outcome in lung adenocarcinoma (ADC), but response of ALK/EGFR-positive tumors to immune therapy is limited. The underlying immune biology is incompletely understood. |
|---|
| DOI: | doi:10.1007/s00262-021-02981-w |
|---|
| URL: | kostenfrei: Volltext: https://doi.org/10.1007/s00262-021-02981-w |
|---|
| | DOI: https://doi.org/10.1007/s00262-021-02981-w |
|---|
| Datenträger: | Online-Ressource |
|---|
| Sprache: | eng |
|---|
| Sach-SW: | ALK fusion |
|---|
| | EGFR mutation |
|---|
| | Immune checkpoint blockade |
|---|
| | Immunosuppression |
|---|
| | Immunotherapy |
|---|
| | Lung adenocarcinoma |
|---|
| K10plus-PPN: | 1844717607 |
|---|
| Verknüpfungen: | → Zeitschrift |
|---|
| |
|
|---|
| | |
|---|
| Lokale URL UB: |  Zum Volltext |
|---|
Deciphering the immunosuppressive tumor microenvironment in ALK- and EGFR-positive lung adenocarcinoma / Budczies, Jan [VerfasserIn]; 14 June 2021 (Online-Ressource)
